Neuropsychiatric Symptoms Related to Neurodegenerative Disease

3
Pipeline Programs
1
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
PIMAVANSERINApproved
pimavanserin
Unknown Company
oral

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
2 programs
2
PimavanserinPhase 31 trial
PimavanserinPhase 31 trial
Active Trials
NCT03623321Completed595Est. May 2023
NCT03575052Completed784Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsPimavanserin
Acadia PharmaceuticalsPimavanserin

Clinical Trials (2)

Total enrollment: 1,379 patients across 2 trials

NCT03623321Acadia PharmaceuticalsPimavanserin

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Start: Jul 2018Est. completion: May 2023595 patients
Phase 3Completed
NCT03575052Acadia PharmaceuticalsPimavanserin

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Start: May 2018Est. completion: May 2022784 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space